{"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions reported with ALPHANATE (incidence >1% of infusions) were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash and chills. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Grifols Biologicals LLC at 1-800-520-2807 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. Hemophilia A In a prospective clinical study with ALPHANATE, 23 patients were exposed to 1217 infusions (median=42, range 2 to 160). The total number of exposure days was 1133, and the total number of months on study across all patients was 234 (19.5 patient years). von Willebrand Disease (VWD) In the prospective clinical study of ALPHANATE[using both ALPHANATE Solvent Detergent (A-SD, a previous generation product) and ALPHANATE Solvent Detergent/Heat Treated (A-SD/HT, the current generation product)] in patients with VWD, adverse reactions occurred in 5 of 36 patients (13.9%) treated with ALPHANATE (A-SD/HT). Sixty-one total adverse reactions were reported in 204 infusions. The majority of adverse reactions were rated as mild (55 of 61 [90.2%]) and six (9.8%) were rated as moderate. Overall, the proportion of infusions associated with adverse reactions was 14 of 204 infusions (6.9%). The most common adverse reactions reported (> 1% of infusions) were pruritus, headache, backpain, paresthesia, respiratory distress, facial edema, pain, rash, and chills. One incident of pulmonary embolism was reported that was considered to have a possible relationship to the product. This patient received a dose of 60 IU VWF:RCo/kg body weight and the FVIII:C level achieved was 290%. In the retrospective study conducted to determine the efficacy and safety of ALPHANATE (A-SD/HT) in a surgical or invasive procedure setting as perioperative prophylaxis against excessive bleeding [see Clinical Studies (14) ], 3 out of 39 patients (7.7%) experienced 6 adverse reactions. Four were considered mild and 2 were considered moderate adverse reactions. The adverse reactions were pruritus, paresthesia (2 events) and hemorrhage, (all considered mild), and one event each of moderate hematocrit decrease and orthostatic hypotension. One adverse reaction (pain) related to the treatment with heat-treated ALPHANATE (A-SD/HT) was reported in the four pediatric patients with VWD during the course of the prospective study and in none of the five pediatric patients in the retrospective clinical study. 6.2 Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during postmarketing use of ALPHANATE: General disorders and administration site conditions: fever, fatigue, and infusion site pain Gastrointestinal disorders: nausea Musculoskeletal and connective tissue disorders: joint pain Immune system disorders: allergic/hypersensitivity reactions"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action ALPHANATE contains antihemophilic factor (FVIII) and von Willebrand factor (VWF), constituents of normal plasma. FVIII is an essential cofactor in activation of factor X leading to formation of thrombin and fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; it also serves as a stabilizing carrier protein for the procoagulant protein FVIII. After administration, ALPHANATE temporarily replaces the missing coagulation FVIII and VWF needed for effective hemostasis. 12.2 Pharmacodynamics There have been no specific pharmacodynamic studies on ALPHANATE. 12.3 Pharmacokinetics Pharmacokinetics in Hemophilia A Following the administration of ALPHANATE during clinical trials, the mean in vivo half-life of FVIII observed in 12 adult patients with severe hemophilia A was 17.9 ± 9.6 hours. In this same study, the in vivo recovery was 96.7 ± 14.5% at 10 minutes post-infusion. Recovery at 10 minutes post-infusion was 2.4 ± 0.4 IU FVIII rise/dL plasma per IU FVIII infused/kg body weight. Pharmacokinetics in von Willebrand Disease (VWD) A pharmacokinetic crossover study was conducted in 14 non-bleeding patients with VWD (1 type 1, 2 type 2A, and 11 type 3) comparing the pharmacokinetics of ALPHANATE (A-SD/HT) and an earlier formulation, ALPHANATE (A-SD). Patients received, in random order at least seven days apart, a single intravenous dose of each product, 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg in patients younger than 18 years of age). Pharmacokinetic parameters were similar for the two products and indicated that they were biochemically equivalent. Pharmacokinetic analysis of ALPHANATE (A-SD/HT) in the 14 patients revealed the following results: the median plasma levels (% normal) of VWF:RCo rose from 10 IU/dL (range: 10 to 27 IU/dL) at baseline to 206 IU/dL (range: 87 to 440 IU/dL) 15 minutes post-infusion; median plasma levels of FVIII:C rose from 5 IU/dL (range: 2 to 114 IU/dL) to 206 IU/dL (range: 110 to 421 IU/dL). The median bleeding time (BT) prior to infusion was 30 minutes (mean, 28.8 ± 4.41 minutes; range: 13.5 to 30 minutes), which shortened to 10.38 minutes (mean, 10.4 ± 3.2 minutes; range: 6 to 16 minutes) 1 hour post-infusion. Following infusion of ALPHANATE (A-SD/HT), the median half-lives for VWF:RCo, FVIII:C and VWF:Ag were 6.91 hours (range: 3.8 to 16.22 hours), 20.92 hours (range: 7.19 to 32.2 hours), and 12.8 hours (range: 10.34 to 17.45 hours), respectively. The median incremental in vivo recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [range: 1.28 to 5.73 (IU/dL)/(IU/kg)] for VWF:RCo and 1.95 (IU/dL)/(IU/kg) [range: 1.33 to 3.32 (IU/dL)/(IU/kg)] for FVIII:C. The pharmacokinetic data in VWD are summarized in Table 6 . Table 6: Pharmacokinetic Data in von Willebrand Disease Parameter Plasma VWF:RCo (Mean ± SD) Plasma FVIII:C (Mean ± SD) Plasma VWF:Ag (Mean ± SD) Number of patients 14 14 14 Mean plasma levels (IU/dL): Baseline 11.86 ± 4.97 21.00 ± 33.83 – Mean plasma levels (IU/dL): 15 minutes post infusion 215.50 ± 101.70 215.29 ± 94.26 – T½ (Half-life in hours) 7.67 ± 3.32 21.58 ± 7.79 13.06 ± 2.20 Incremental in vivo recovery in (IU/dL)/(IU/kg) 3.29 ± 1.46 2.13 ± 0.58 – Following infusion of both ALPHANATE (A-SD) and ALPHANATE (A-SD/HT), an increase in the size of VWF multimers was seen and persisted for at least 24 hours. The shortening of the BT was transient, lasting less than 6 hours following treatment and did not correlate with the presence of large and intermediate size VWF multimers."],"clinical_pharmacology_table":["<table ID=\"t6\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"100%\"><caption>Table 6: Pharmacokinetic Data in von Willebrand Disease</caption><colgroup><col align=\"left\" width=\"31.07%\"/><col align=\"left\" width=\"22.37%\"/><col align=\"left\" width=\"23.42%\"/><col align=\"left\" width=\"23.12%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Parameter</content> </td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma VWF:RCo</content> (Mean &#xB1; SD)</td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma FVIII:C</content> (Mean &#xB1; SD)</td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma VWF:Ag</content> (Mean &#xB1; SD)</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Number of patients</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Mean plasma levels (IU/dL):  Baseline</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">11.86 &#xB1; 4.97</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">21.00 &#xB1; 33.83</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Mean plasma levels (IU/dL):  15 minutes post infusion</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">215.50 &#xB1; 101.70</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">215.29 &#xB1; 94.26</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">T&#xBD; (Half-life in hours)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">7.67 &#xB1; 3.32</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">21.58 &#xB1; 7.79</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">13.06 &#xB1; 2.20</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Incremental <content styleCode=\"italics\">in vivo </content>recovery  in (IU/dL)/(IU/kg)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">3.29 &#xB1; 1.46</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">2.13 &#xB1; 0.58</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr></tbody></table>"],"clinical_studies":["14 CLINICAL STUDIES Von Willebrand Disease Prospective Study In a prospective, multi-center clinical study, 37 patients with VWD (6 Type 1, 19 Type 2, 12 Type 3) underwent 59 surgical procedures for which ALPHANATE (A-SD) or ALPHANATE (A-SD/HT) was administered [21 patients received ALPHANATE (A-SD), 18 received ALPHANATE (A-SD/HT), and 2 received both products] for bleeding prophylaxis (see Table 7 ). An initial pre-operative infusion of 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg for patients less than 18 years of age), was administered one hour before surgery. A blood sample was obtained 15 minutes after the initial infusion for the determination of the plasma FVIII:C level. The level had to equal or exceed 100% of normal for an operation to proceed. No cryoprecipitate or alternative FVIII product was administered during these surgical procedures. Platelets were required in two patients. The protocol permitted intra-operative infusions of ALPHANATE (A-SD) and ALPHANATE (A-SD/HT) at 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg for patients less than 18 years of age) to be administered as required according to the judgment of the investigator. Table 7: Number of and Types of Surgical Procedures with ALPHANATE (A-SD) or ALPHANATE (A-SD/HT) Treatment Type of Surgical Procedure A-SD (N = 21 patients) A-SD/HT (N = 18 patients) Total (N=37 patients) Dental 14 6 20 Dermatologic 1 1 2 Gastrointestinal 4 4 8 Gastrointestinal (diagnostic) 6 0 6 Genitourinary 0 2 2 Gynecologic 2 1 3 Head and neck 1 1 2 Orthopedic 4 3 7 Vascular 3 6 9 Total number of procedures 35 24 59 Two patients received both preparations; the total number of patients is therefore less than the sum of the columns. Post-operative infusions at doses of 40 to 60 IU VWF:RCo/kg (50 to 75 IU VWF:RCo/kg for pediatric patients) were administered at 8 to 12-hour intervals until healing had occurred. For maintenance of secondary hemostasis (after primary hemostasis was achieved), the dose was reduced after the third post-operative day [see Dosage and Administration (2.1) ] . Overall, in the surgical procedures using either product, the BT at 30 minutes post-infusion was fully corrected in 18 (32.7%) cases, partially corrected in 24 (43.6%) cases, not corrected in 12 (21.8%) cases, and was not done in one case (1.8%). Overall, the mean blood loss was lower than predicted prospectively. Surgical infusion summary data are included in Table 8 . Table 8: Prophylaxis with ALPHANATE (A-SD) and/or ALPHANATE (A-SD/HT) in Surgery Parameter A-SD A-SD/HT Total Number of patients 21 18 37 Two patients received both products. Number of surgical procedures 35 24 59 Median number of infusions per surgical procedure (range) 3 (1-13) 4 (1 – 18) 4 (1-18) Median dosage IU VWF:RCo/kg, Infusion #1 (range) 59.8 (19.8-75.1) 59.9 (40.6 – 75.0) 59.9 (19.8-75.1) Median dosage IU VWF:RCo/kg, Infusion ≥ #2 combined (range) 40.0 (4.5-75.1) 40.0 (10.0 – 63.1) 40.0 (4.5-75.1) Additionally, surgical procedures using ALPHANATE SD/HT only were categorized as major, minor or invasive procedures according to definitions used in the study. The outcome of each surgery was evaluated according to a clinical rating scale (excellent, good, poor or none) and was considered successful if the outcome was excellent or good. Study results also were evaluated independently by two referees with clinical experience in this field in the same way (surgery categorization and outcome of each surgery according to a clinical rating scale). There was a high level of agreement between the referee evaluations and the analyzed outcome data, with a decrease of only a single success in achieving hemostasis (21/24 [referees evaluation] vs. 22/24 [investigators evaluation]). Retrospective Study A retrospective, multi-center study was performed to assess the efficacy of ALPHANATE (A-SD/HT) as replacement therapy in preventing excessive bleeding in patients with congenital VWD undergoing surgical or invasive procedures, for whom DDAVP was ineffective or inadequate. A total of 61 surgeries/procedures in 39 patients were evaluated. Of the 39 patients, 18 had Type 1 VWD (46.2%); 12 patients (30.8%) had Type 2 VWD, and 9 patients (23.1%) had Type 3 VWD. Median age was 40 years; approximately one-half of the patients were male. The primary efficacy variable was the overall treatment outcome for each surgical or invasive procedure, as rated by the investigator using a 4-point verbal rating scale (VRS): “excellent,” “good,” “poor,” or “none (no indication of efficacy).” The categorization of the replacement treatment outcome was based upon the investigator’s clinical experience and defined in Table 9 . Table 9: Rating Scale and Clinical Efficacy of ALPHANATE Therapy Rating Hemostasis The efficacy assessment period included the entire perioperative period. Dosing Excellent Hemostasis not different from that expected for patients without known bleeding disorders. No upward dosage adjustment for ALPHANATE replacement therapy. Good Hemostasis slightly inferior from that expected for patients without known bleeding disorders but judged as not clinically relevant. Minor upward dosage adjustment for ALPHANATE replacement therapy. Poor Less hemostasis than expected for patients without known bleeding disorders attributed to VWD despite ALPHANATE replacement therapy. Relevant upward dosage adjustment for ALPHANATE replacement therapy. No need for alternative therapy. None Severe bleeding attributed to VWD despite ALPHANATE replacement therapy. Relevant upward dosage adjustment for ALPHANATE replacement therapy and/or need for alternative unexpected therapy. In addition, an independent referee committee was convened to evaluate the efficacy outcomes. More than 90% of the surgical outcomes received an investigator and referee’s overall and daily rating of “effective” (“excellent” or “good”) in achieving hemostasis/preventing bleeding. The majority of ratings were considered “excellent” (≥ 81.3% in each VWD type). Nine Type 3 patients underwent 1 major and 15 minor procedures. Two procedures (1 major and 1 minor) in 1 patient with Type 3 VWD received an overall efficacy rating of “none,” and one minor procedure in a patient with Type 2 VWD received an overall efficacy rating of “poor.”"],"clinical_studies_table":["<table ID=\"t7\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"80%\"><caption>Table 7: Number of and Types of Surgical Procedures with ALPHANATE (A-SD) or ALPHANATE (A-SD/HT) Treatment</caption><colgroup><col align=\"left\" width=\"49.75%\"/><col align=\"left\" width=\"20.35%\"/><col align=\"left\" width=\"17.2%\"/><col align=\"left\" width=\"12.7%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Type of Surgical Procedure</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">A-SD  (N = 21 patients)</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">A-SD/HT (N = 18 patients)</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Total  (N=37</content><content styleCode=\"bold\"> patients)</content></td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Dental</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">14</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\">20</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Dermatologic</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">2</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Gastrointestinal</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">8</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Gastrointestinal (diagnostic)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">6</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Genitourinary</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">2</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">2</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Gynecologic</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">2</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">3</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Head and neck</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">2</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Orthopedic</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">3</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">7</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Vascular</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">3</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">9</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Total number of procedures</content></td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\"><content styleCode=\"bold\">35</content></td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\"><content styleCode=\"bold\">24</content></td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\"><content styleCode=\"bold\">59</content></td></tr></tbody></table>","<table ID=\"t8\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"80%\"><caption>Table 8: Prophylaxis with ALPHANATE (A-SD) and/or ALPHANATE (A-SD/HT) in Surgery</caption><colgroup><col align=\"left\" width=\"40.2%\"/><col align=\"left\" width=\"18.55%\"/><col align=\"left\" width=\"20.62%\"/><col align=\"left\" width=\"20.62%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Parameter</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">A-SD</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">A-SD/HT</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Total</content></td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">Number of patients </td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">21</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">18</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">37<footnote ID=\"SPLSERV-E6251E7E-B351-AD67-1926-D98695657ADA\">Two patients received both products.</footnote></td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">Number of surgical procedures</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">35</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">24</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">59</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">Median number of infusions per surgical procedure (range)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">3 (1-13)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">4 (1 &#x2013; 18)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">4 (1-18)</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">Median dosage IU VWF:RCo/kg, Infusion #1 (range)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">59.8 (19.8-75.1)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">59.9 (40.6 &#x2013; 75.0)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">59.9 (19.8-75.1)</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">Median dosage IU VWF:RCo/kg, Infusion &#x2265; #2 combined (range)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">40.0 (4.5-75.1)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">40.0 (10.0 &#x2013; 63.1)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"top\">40.0 (4.5-75.1)</td></tr></tbody></table>","<table ID=\"SPLSERV-A2522A9D-E08C-6D64-E710-977D2D2B900F\" cellpadding=\"4\" cellspacing=\"0\" styleCode=\"Noautorules\" width=\"80%\"><caption>Table 9: Rating Scale and Clinical Efficacy of ALPHANATE Therapy</caption><colgroup><col styleCode=\"Botrule Lrule Rrule Toprule\"/><col styleCode=\"Botrule Lrule Rrule Toprule\"/><col styleCode=\"Botrule Lrule Rrule Toprule\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Rating</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Hemostasis</content><footnote ID=\"SPLSERV-EEC35933-7B47-7E07-EE79-27B6B9F4246B\">The efficacy assessment period included the entire perioperative period. </footnote></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Dosing<footnoteRef IDREF=\"SPLSERV-EEC35933-7B47-7E07-EE79-27B6B9F4246B\"/></content></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Excellent </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Hemostasis not different from that expected for patients without known bleeding disorders. </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> No upward dosage adjustment for ALPHANATE replacement therapy. </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Good </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Hemostasis slightly inferior from that expected for patients without known bleeding disorders but judged as not clinically relevant.</td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Minor upward dosage adjustment for ALPHANATE replacement therapy. </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Poor </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Less hemostasis than expected for patients without known bleeding disorders attributed to VWD despite ALPHANATE replacement therapy.</td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Relevant upward dosage adjustment for ALPHANATE replacement therapy. No need for alternative therapy.  </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> None </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Severe bleeding attributed to VWD despite ALPHANATE replacement therapy. </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Relevant upward dosage adjustment for ALPHANATE replacement therapy and/or need for alternative unexpected therapy. </td></tr></tbody></table>"],"contraindications":["4 CONTRAINDICATIONS None. None. ( 4 )"],"description":["11 DESCRIPTION ALPHANATE (antihemophilic factor/von Willebrand factor complex [human]) is a sterile, lyophilized concentrate of FVIII (AHF) and von Willebrand Factor (VWF). ALPHANATE is prepared from pooled human plasma by cryoprecipitation of FVIII, fractional solubilization, and further purification employing heparin-coupled, cross-linked agarose which has an affinity to the heparin binding domain of VWF/FVIII:C complex. The product is treated with a mixture of tri-n-butyl phosphate (TNBP) and polysorbate 80 to inactivate enveloped viruses. The product is also subjected to an 80 °C heat treatment step for 72 hours to inactivate enveloped and non-enveloped viruses. However, no procedure has been shown to be totally effective in removing viral infectivity from coagulation factor products. ALPHANATE is labeled with the antihemophilic factor potency (FVIII:C activity) in International Units (IU) FVIII/vial and with VWF:RCo activity expressed in IU VWF:RCo/vial. The activities are referenced to their respective international standards established by the World Health Organization. One IU of FVIII or one IU of VWF:RCo is approximately equal to the amount of FVIII or VWF:RCo activity in 1 mL of freshly-pooled human plasma. ALPHANATE contains human albumin as a stabilizer, resulting in a final container concentrate with a specific activity of at least 5 FVIII:C IU/mg total protein. ALPHANATE contains no preservatives. The composition of ALPHANATE after reconstitution is provided in Table 4 : Table 4: Composition (per Vial) of ALPHANATE Following Reconstitution with Sterile Water for Injection, U.S.P. Ingredient Units 250 IU vial 500 IU vial 1000 IU vial 1500 IU vial 2000 IU vial Factor VIII IU 250 500 1000 1500 2000 von Willebrand Factor IU per 1000 IU FVIII > 400 > 400 > 400 > 400 > 400 Albumin (Human) mg 25 25 50 50 50 Arginine mg 90 90 175 175 175 Histidine mg 20 20 40 40 40 Water for Injection Supplied in a separate diluent vial mL 5 5 10 10 10 Virus Reduction Capacity The results of virus validation studies performed to determine virus reduction factors associated with several steps in the manufacturing process of ALPHANATE are summarized in Table 5 . In vitro inactivation studies to evaluate the solvent detergent treatment (0.3% TNBP and 1% polysorbate 80) step in the manufacture of ALPHANATE were conducted to assess the capability of the step to inactivate enveloped viruses, such as Human Immunodeficiency viruses (HIV), as well as marker viruses such as Sindbis virus (SIN, a model for Hepatitis C virus (HCV)), Vesicular Stomatitis virus (VSV, a model for large, enveloped RNA virus), Bovine Herpes virus (BHV, a model for Hepatitis B virus) and Bovine Viral Diarrhea virus (BVD, a model for HCV). In vitro inactivation studies to evaluate the dry heat treatment (80 °C, 72 hours) step in the manufacture of ALPHANATE were conducted to assess the capability of the step to inactivate both enveloped and non-enveloped viruses, such as Hepatitis A virus (HAV), human Poliovirus Sabin type 2 (POL, a model for HAV), Canine Parvovirus (CPV, a model for Parvovirus B19), BHV and BVD. Other steps in the manufacturing process of ALPHANATE (precipitation with 3.5% polyethylene glycol (PEG), heparin affinity chromatography and lyophilization) were also evaluated for virus elimination capability using several enveloped and non-enveloped viruses as shown in Table 5 . Table 5: Virus Log 10 Reduction Virus (Model Virus for) 3.5% PEG Precipitation Solvent- Detergent Column Chromatography Lyophilization Dry Heat Cycle (80 °C, 72 hr) Total Log 10 Reduction BHV Abbreviations used: BHV = Bovine Herpes Virus (model for HBV); BVD = Bovine Viral Diarrhea Virus (model for HCV); POL = Human Poliovirus Sabin type 2 (model for HAV); CPV = Canine Parvovirus (model for Parvovirus B19); VSV = Vesicular Stomatitis Virus (model for large, enveloped RNA virus); SIN = Sindbis Virus (model for HCV); HIV-1 and HIV-2 = Human Immunodeficiency Viruses; HAV = hepatitis A virus (HBV) < 1.0 ≥ 8.0 7.6 1.3 2.1 ≥ 19.0 BVD (HCV) < 1.0 ≥ 4.5 < 1.0 < 1.0 ≥ 4.9 ≥ 9.4 POL (HAV) 3.3 – < 1.0 3.4 ≥ 2.5 ≥ 9.2 CPV (B19) 1.2 – < 1.0 < 1.0 4.1 5.3 VSV – ≥ 4.1 – – – ≥ 4.1 SIN (HCV) – ≥ 4.7 – – – ≥ 4.7 HIV–1 < 1.0 ≥ 11.1 ≥ 2.0 – – ≥ 13.1 HIV–2 – ≥ 6.1 – – – ≥ 6.1 HAV – – – 2.1 ≥ 5.8 ≥ 7.9 Additionally, the manufacturing process was investigated for its capacity to decrease infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents. Several of the individual production steps in ALPHANATE manufacturing process have been shown to decrease TSE infectivity of an experimental model agent. TSE reduction steps include: 3.5% polyethylene glycol precipitation (3.23 log 10 ), affinity chromatography (3.50 log 10 ) and saline precipitation (1.36 log 10 ). These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed."],"description_table":["<table ID=\"SPLSERV-62cb7fa0-30c5-4e05-9d6e-85a4fec6161f\" cellpadding=\"4\" cellspacing=\"0\" styleCode=\"Noautorules Botrule\" width=\"100%\"><caption>Table 4: Composition (per Vial) of ALPHANATE Following Reconstitution with Sterile Water for Injection, U.S.P.</caption><tbody><tr><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Ingredient</content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Units</content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">250 IU  vial</content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">500 IU  vial</content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">1000 IU  vial</content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">1500 IU  vial </content></td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">2000 IU  vial</content></td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule Toprule\">Factor VIII</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">IU</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">250</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">500</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">1000</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">1500</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">2000</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> von Willebrand Factor </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">IU per 1000 IU  FVIII</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> &gt; 400 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> &gt; 400 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> &gt; 400 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">&gt; 400</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">&gt; 400</td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule Toprule\"> Albumin (Human) </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">mg</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\"> 25 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">25</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\"> 50 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\"> 50 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">50</td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule Toprule\"> Arginine </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">mg</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\"> 90 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">90</td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\"> 175 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\"> 175 </td><td align=\"center\" styleCode=\"Lrule Rrule Toprule\">175</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule Toprule\"> Histidine </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">mg</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"> 20 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">20</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"> 40 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 40 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">40</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule Toprule\">Water for Injection<footnote ID=\"SPLSERV-D2AE2B67-811B-DE10-0623-1CE7688B3E60\">Supplied in a separate diluent vial</footnote></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">mL</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"> 5 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">5</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"> 10 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 10 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\">10</td></tr></tbody></table>","<table ID=\"t5\" styleCode=\"Noautorules\" width=\"100%\"><caption>Table 5: Virus Log<sub>10</sub> Reduction</caption><colgroup><col align=\"left\" width=\"12.95%\"/><col align=\"left\" width=\"13.77%\"/><col align=\"left\" width=\"12.15%\"/><col align=\"left\" width=\"19.05%\"/><col align=\"left\" width=\"15.37%\"/><col align=\"left\" width=\"15.57%\"/><col align=\"left\" width=\"11.11%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\"><content styleCode=\"bold\">Virus</content> <content styleCode=\"bold\">(Model Virus for)</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">3.5% PEG</content> <content styleCode=\"bold\">Precipitation</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Solvent- Detergent</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Column</content> <content styleCode=\"bold\">Chromatography</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Lyophilization</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Dry Heat Cycle</content> <content styleCode=\"bold\">(80 &#xB0;C, 72 hr)</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Total Log<sub>10</sub></content> <content styleCode=\"bold\">Reduction</content></td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">BHV<footnote ID=\"SPLSERV-37B6DB57-D6AF-8137-DAC9-736D126AC554\">Abbreviations used: BHV = Bovine Herpes Virus (model for HBV); BVD = Bovine Viral Diarrhea Virus (model for HCV); POL = Human Poliovirus Sabin type 2 (model for HAV); CPV = Canine Parvovirus (model for Parvovirus B19); VSV = Vesicular Stomatitis Virus (model for large, enveloped RNA virus); SIN = Sindbis Virus (model for HCV); HIV-1 and HIV-2 = Human Immunodeficiency Viruses; HAV = hepatitis A virus</footnote> (HBV)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 8.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">7.6</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">1.3</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">2.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 19.0</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">BVD (HCV)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.5</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.9</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 9.4</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">POL (HAV)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">3.3</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">3.4</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 2.5</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 9.2</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">CPV (B19)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">1.2</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">4.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">5.3</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">VSV</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.1</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">SIN (HCV)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.7</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 4.7</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">HIV&#x2013;1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&lt; 1.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 11.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 2.0</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 13.1</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">HIV&#x2013;2</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 6.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 6.1</td></tr><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule\" valign=\"middle\">HAV</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2013;</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">2.1</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 5.8</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"middle\">&#x2265; 7.9</td></tr></tbody></table>"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For intravenous injection after reconstitution only. ALPHANATE contains the labeled amount of factor VIII (FVIII) expressed in International Units (IU) FVIII/vial and von Willebrand Factor (VWF): Ristocetin Cofactor activity in IU VWF:RCo/vial. ( 2.1 ) Treatment and Prevention of Bleeding Episodes and Excess Bleeding During and After Surgery in Patients with Hemophilia A. Dose (units) = body weight (kg) x desired FVIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL). ( 2.1 ) Dosing frequency determined by the type of bleeding episode and the recommendation of the treating physician. ( 2.1 ) Treatment and Prevention of Excess Bleeding During and After Surgery or Other Invasive Procedures in Patients with von Willebrand Disease. Adults: Pre-operative dose of 60 IU VWF:RCo/kg body weight; subsequent doses of 40 IU to 60 IU VWF:RCo/kg body weight. ( 2.1 ) Pediatric: Pre-operative dose of 75 IU VWF:RCo/kg body weight; subsequent doses of 50 IU to 75 IU VWF:RCo/kg body weight. ( 2.1 ) 2.1 Dose For intravenous injection after reconstitution only Each vial of ALPHANATE has the antihemophilic factor (AHF) potency (FVIII:C activity) expressed in International Units (IU) FVIII/vial on the label. Additionally, ALPHANATE contains von Willebrand Factor:Ristocetin Cofactor (VWF:RCo), which is expressed in IU VWF:RCo/vial for the treatment of VWD. Treatment and Prevention of Bleeding Episodes and Excess Bleeding During and After Surgery in Patients with Hemophilia A Dosage and duration of treatment depend on the severity of the FVIII deficiency, the location and extent of bleeding, presence of inhibitors, and the patient’s clinical condition. Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. Calculate dosing requirements and frequency of dosing on the basis of an expected initial response of 2% of normal FVIII:C increase per IU FVIII:C/kg body weight administered. Calculate the expected in vivo peak increase in FVIII level expressed as IU/dL (or % of normal) using the following formulas: Dosage (international units) = body weight (kg) x desired FVIII rise (IU/dL or % normal) x 0.5 (IU/kg per IU/dL) or IU/dL (or % of normal) = [Total Dose (IU)/body weight (kg)] x 2 Titrate dose and frequency to the patient’s clinical response, including individualized needs, severity of the deficiency, severity of the hemorrhage, presence of inhibitors, and FVIII level desired. Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses to ALPHANATE. Table 1 provides dosage guidelines for the control and prevention of bleeding episodes in hemophilia A patients. Dosing should aim at maintaining a plasma factor VIII activity level at or above the plasma levels (in IU/dL or in % of normal) outlined in the table. Table 1: Dosage Guidelines for Patients with Hemophilia A Type of Bleeding FVIII:C Level Required (% of normal) Doses (IU/kg) Frequency of Doses (hours) Duration of Therapy (days) Minor Large bruises Significant cuts or scrapes Uncomplicated joint hemorrhage 30% 15 12 (twice daily) Until hemorrhage stops and healing has been achieved (1–2 days). Moderate Nose, mouth and gum bleeds Dental extractions Hematuria 50% 25 12 (twice daily) Until healing has been achieved (2–7 days, on average). Major Initial dose Joint hemorrhage Muscle hemorrhage Major trauma Hematuria Intracranial and intraperitoneal bleeding 80% to 100% 40 to 50 12 (twice daily) For at least 3–5 days Major Maintenance dose Joint hemorrhage Muscle hemorrhage Major trauma Hematuria Intracranial and intraperitoneal 80% to 100% 25 12 (twice daily) Until healing has been achieved for up to 10 days. Intracranial hemorrhage may require prophylaxis therapy for up to 6 months. Surgery: Prior to surgery 80% to 100% 40 to 50 Once - Surgery: After surgery 60% to 100% 30 to 50 12 (twice daily) For the next 7–10 days, or until healing has been achieved. Monitoring parameters: Monitor plasma FVIII levels periodically to evaluate individual patient response to the dosage regimen. If dosing studies have determined that a particular patient exhibits a lower/higher than expected response and shorter/longer half-life, adjust the dose and the frequency of dosing accordingly. Failure to achieve the expected plasma FVIII:C level or to control bleeding after an appropriately calculated dosage may be indicative of the development of an inhibitor (an antibody to FVIII:C). Quantitate the inhibitor level by appropriate laboratory procedures and document its presence. Treatment with ALPHANATE in such cases must be individualized. Treatment and Prevention of Excess Bleeding During and After Surgery or Other Invasive Procedures in Patients with von Willebrand Disease The ratio of VWF:RCo to FVIII in ALPHANATE varies by lot, so with each new lot, check IU VWF:RCo/vial to ensure accurate dosing. Dosage and duration of treatment depend on the severity of the VWF deficiency, the location and extent of bleeding, and the patient’s clinical condition. Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. The median incremental in vivo recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [mean, 3.29 ± 1.46 (IU/dL)/(IU/kg); range: 1.28 to 5.73 (IU/dL)/(IU/kg)] for VWF:RCo and 1.95 (IU/dL)/(IU/kg) [mean, 2.13 ± 0.58 (IU/dL)/(IU/kg); range: 1.33 to 3.32 (IU/dL)/(IU/kg)] for FVIII:C. Table 2 provides dosing guidelines for pediatric and adult patients with VWD with minor bleeding or undergoing minor surgery. Table 2: Dosage Guidelines for Patients with von Willebrand Disease for Minor Surgery or Minor Bleeding Parameter VWF:RCo Target FVIII:C Activity Levels Pre-operative/pre-procedure dose: adult 60 IU VWF:RCo/kg body weight 40 IU/dL to 50 IU/dL Maintenance dose: adult 40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days 40 IU/dL to 50 IU/dL Pre-operative/pre-procedure dose: pediatric 75 IU VWF:RCo/kg body weight 40 IU/dL to 50 IU/dL Maintenance dose: pediatric 50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days 40 IU/dL to 50 IU/dL Therapeutic Goal (Trough): >50 IU/dL >50 IU/dL Safety Monitoring: Peak and trough at least once daily Peak and trough at least once daily Safety Parameter: Should not exceed 150 IU/dL Should not exceed 150 IU/dL Table 3 provides dosing guidelines for pediatric and adult patients with VWD with major bleeding or major surgery. Table 3: Dosage Guidelines for Patients with von Willebrand Disease for Major Surgery or Major Bleeding (Except Type 3 Patients Undergoing Major Surgery) Parameter VWF:RCo Target FVIII:C Activity Levels Pre-operative/pre-procedure dose: adult 60 IU VWF:RCo/kg body weight 100 IU/dL Maintenance dose: adult 40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days 100 IU/dL Pre-operative/pre-procedure dose: pediatric 75 IU VWF:RCo/kg body weight 100 IU/dL Maintenance dose: pediatric 50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days 100 IU/dL Therapeutic Goal (Trough): >50 IU/dL >50 IU/dL Safety Monitoring: Peak and trough at least daily Peak and trough at least daily Safety Parameter: Should not exceed 150 IU/dL Should not exceed 150 IU/dL 2.2 Reconstitution Always use aseptic technique. Ensure that concentrate (ALPHANATE) and diluent (Sterile Water for Injection, USP) are at room temperature (but not above 37 ˚C) before reconstitution. Remove the plastic flip off cap from the diluent vial. Gently swab the exposed stopper surface with a cleansing agent such as alcohol trying to avoid leaving any excess cleansing agent on the stopper. Open the Mix2Vial ® package by peeling away the lid ( Figure 1 ). Leave the Mix2Vial in the clear outer packaging. Place the diluent vial upright on an even surface and hold the vial tight and pick up the Mix2Vial in its clear outer packaging. Holding the diluent vial securely, push the blue end of the Mix2Vial vertically down through the diluent vial stopper ( Figure 2 ). While holding onto the diluent vial, carefully remove the clear outer packaging from the Mix2Vial set, ensuring the Mix2Vial remains attached to the diluent vial ( Figure 3 ). Place the product vial upright on an even surface, invert the diluent vial with the Mix2Vial attached. While holding the product vial securely on a flat surface, push the clear end of the Mix2Vial set vertically down through the product vial stopper ( Figure 4 ). The diluent will automatically transfer out of its vial into the product vial. NOTE: If the Mix2Vial is connected at an angle, the vacuum may be released from the product vial and the diluent will not transfer into the product vial. With the diluent and product vials still attached to the Mix2Vial, gently swirl the product vial to ensure the product is fully dissolved ( Figure 5 ). Reconstitution requires less than 5 minutes. Do not shake the vial. Disconnect the Mix2Vial into two separate pieces ( Figure 6 ) by holding each vial adapter and twisting counterclockwise. After separating, discard the diluent vial with the blue end of the Mix2Vial. Draw air into an empty, sterile syringe. Keeping the product vial upright with the clear end of the Mix2Vial attached, screw the disposable syringe onto the luer lock portion of the Mix2Vial device by pressing and twisting clockwise. Inject air into the product vial. While keeping the syringe plunger depressed, invert the system upside down and draw the reconstituted product into the syringe by pulling the plunger back slowly ( Figure 7 ). When the reconstituted product has been transferred into the syringe, firmly hold the barrel of the syringe and the clear vial adapter (keeping the syringe plunger facing down) and unscrew the syringe from the Mix2Vial ( Figure 8 ). Hold the syringe upright and push the plunger until no air is left in the syringe. Attach the syringe to a venipuncture set. NOTE: If the same patient is to receive more than one vial of concentrate, the contents of two vials may be drawn into the same syringe through a separate unused Mix2Vial set before attaching to the venipuncture set. When reconstitution procedure is strictly followed, a few small particles may occasionally remain. The Mix2Vial set will remove particles and the labeled potency will not be reduced. Discard all reconstitution equipment after use into the appropriate safety container. Do not reuse. Use the prepared drug as soon as possible within 3 hours after reconstitution. 2.3 Administration For intravenous use after reconstitution only Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not refrigerate after reconstitution. Store reconstituted ALPHANATE at room temperature (not to exceed 30 °C) prior to administration but administer intravenously within three hours. Use plastic disposable syringes. Do not administer ALPHANATE at a rate exceeding 10 mL/minute. Discard any unused contents into the appropriate safety container."],"dosage_and_administration_table":["<table ID=\"SPLSERV-8E3AD855-E689-F686-A659-46872AF5F29F\" cellpadding=\"4\" cellspacing=\"0\" styleCode=\"Noautorules Botrule\" width=\"80%\"><caption>Table 1: Dosage Guidelines for Patients with Hemophilia A</caption><colgroup><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/><col width=\"20%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Type of Bleeding </content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">FVIII:C Level  Required  </content><content styleCode=\"bold\">(% of normal)</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Doses </content><content styleCode=\"bold\">(IU/kg)</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Frequency of  Doses </content><content styleCode=\"bold\">(hours)</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Duration of Therapy  </content><content styleCode=\"bold\">(days)</content></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Minor  </content>Large bruises  Significant cuts or scrapes  Uncomplicated joint hemorrhage</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 30%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 15 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 12 (twice daily) </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Until hemorrhage stops and healing has been achieved (1&#x2013;2 days). </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Moderate  </content>Nose, mouth and gum bleeds  Dental extractions  Hematuria</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 50%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 25 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 12  (twice daily) </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Until healing has been achieved (2&#x2013;7 days, on average). </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Major <content styleCode=\"bold\">Initial dose</content></content> Joint hemorrhage  Muscle hemorrhage  Major trauma  Hematuria  Intracranial and intraperitoneal bleeding</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 80% to 100%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">40 to 50 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> 12  (twice daily) </td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> For at least 3&#x2013;5 days   </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Major </content><content styleCode=\"bold\">Maintenance dose</content> Joint hemorrhage  Muscle hemorrhage  Major trauma  Hematuria  Intracranial and intraperitoneal</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">80% to 100%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">25</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">12  (twice daily)</td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Until healing has been achieved for up to 10 days.  Intracranial hemorrhage may require prophylaxis therapy for up to 6 months.</td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Surgery: Prior to  surgery</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">80% to 100%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">40 to 50</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Once</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">-</td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Surgery: After  surgery</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">60% to 100%</td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">30 to 50 </td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">12  (twice daily)</td><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">For the next 7&#x2013;10 days, or until healing has been achieved.</td></tr></tbody></table>","<table ID=\"t2\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"80%\"><caption>Table 2: Dosage Guidelines for Patients with von Willebrand Disease for Minor Surgery or Minor Bleeding</caption><colgroup><col align=\"left\" width=\"24.72%\"/><col align=\"left\" width=\"53.68%\"/><col align=\"left\" width=\"21.59%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Parameter</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">VWF:RCo</content></td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"middle\"><content styleCode=\"bold\">Target </content><content styleCode=\"bold\">FVIII:C  Activity Levels</content></td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\">Pre-operative/pre-procedure  dose:<content styleCode=\"bold\"> adult</content></td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">60 IU VWF:RCo/kg body weight</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">40 IU/dL to 50 IU/dL</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Maintenance dose:<content styleCode=\"bold\"> adult</content></td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">40 IU/dL to 50 IU/dL</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Pre-operative/pre-procedure  dose:<content styleCode=\"bold\"> pediatric</content></td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">75 IU VWF:RCo/kg body weight</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">40 IU/dL to 50 IU/dL</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Maintenance dose:<content styleCode=\"bold\"> pediatric</content></td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">40 IU/dL to 50 IU/dL</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Therapeutic Goal (Trough):</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">&gt;50 IU/dL</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">&gt;50 IU/dL</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Safety Monitoring:</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">Peak and trough at least once daily</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">Peak and trough at least once daily</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"top\">Safety Parameter:</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">Should not exceed 150 IU/dL</td><td align=\"left\" styleCode=\"Botrule Rrule\" valign=\"top\">Should not exceed  150 IU/dL</td></tr></tbody></table>","<table ID=\"SPLSERV-0306908e-3bc9-45c1-b818-4df93698db93\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"80%\"><caption>Table 3: Dosage Guidelines for Patients with von Willebrand Disease for Major Surgery or Major Bleeding (Except Type 3 Patients Undergoing Major Surgery)</caption><colgroup><col width=\"24.72%\"/><col width=\"53.68%\"/><col width=\"21.59%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Parameter</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">VWF:RCo</content></td><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Target FVIII:C  Activity Levels</content></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Pre-operative/pre-procedure  dose:<content styleCode=\"bold\"> adult</content></td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 60 IU VWF:RCo/kg body weight </td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 100 IU/dL </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Maintenance dose: <content styleCode=\"bold\">adult</content></td><td styleCode=\"Botrule Rrule\" valign=\"top\">40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days</td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 100 IU/dL </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Pre-operative/pre-procedure  dose:<content styleCode=\"bold\"> pediatric</content></td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 75 IU VWF:RCo/kg body weight</td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 100 IU/dL </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Maintenance dose: <content styleCode=\"bold\">pediatric</content></td><td styleCode=\"Botrule Rrule\" valign=\"top\">50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days</td><td styleCode=\"Botrule Rrule\" valign=\"top\"> 100 IU/dL </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Therapeutic Goal (Trough):</td><td styleCode=\"Botrule Rrule\" valign=\"top\"> &gt;50 IU/dL </td><td styleCode=\"Botrule Rrule\" valign=\"top\"> &gt;50 IU/dL </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"> Safety Monitoring: </td><td styleCode=\"Botrule Rrule\" valign=\"top\"> Peak and trough at least daily </td><td styleCode=\"Botrule Rrule\" valign=\"top\"> Peak and trough at least daily </td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">Safety Parameter:</td><td styleCode=\"Botrule Rrule\" valign=\"top\"> Should not exceed 150 IU/dL </td><td styleCode=\"Botrule Rrule\" valign=\"top\"> Should not exceed 150 IU/dL </td></tr></tbody></table>"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS ALPHANATE is available as a lyophilized powder for intravenous injection after reconstitution. It is available in the following potencies: 250 IU FVIII/5 mL single-dose vial 500 IU FVIII/5 mL single-dose vial 1000 IU FVIII/10 mL single-dose vial 1500 IU FVIII/10 mL single-dose vial 2000 IU FVIII/10 mL single-dose vial ALPHANATE is available as a lyophilized powder for intravenous injection after reconstitution in single-dose vials containing 250, 500, 1000, 1500 and 2000 IU FVIII. ( 3 )."],"effective_time":"20260825","geriatric_use":["8.5 Geriatric Use The safety and effectiveness of ALPHANATE have not been studied in geriatric patients ≥ 65 years of age."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied ALPHANATE is supplied in sterile, lyophilized form in a single-dose vial with a vial of diluent (Sterile Water for Injection, USP) and a Mix2Vial filter transfer set. IU activity of FVIII and VWF:RCo are stated on the carton and label of each vial. ALPHANATE is available in the following potencies and color coded based upon assay on the carton and label as follows: Potency NDC Assay Color Code 250 IU FVIII/5 mL single-dose vial 68516-4616-1 250 IU FVIII Range – gray box 500 IU FVIII/5 mL single-dose vial 68516-4617-1 500 IU FVIII Range - green box 1000 IU FVIII/10 mL single-dose vial 68516-4618-2 1000 IU FVIII Range – blue box 1500 IU FVIII/10 mL single-dose vial 68516-4619-2 1500 IU FVIII Range – orange box 2000 IU FVIII/10 mL single-dose vial 68516-4620-2 2000 IU FVIII Range - magenta box Storage and Handling ALPHANATE is stable for three years, up to the expiration date printed on its label, provided that the storage temperature does not exceed 25 °C (77 °F). Do not freeze."],"how_supplied_table":["<table styleCode=\"Noautorules\" width=\"100%\"><colgroup><col align=\"left\" width=\"37.8%\"/><col align=\"left\" width=\"28.86%\"/><col align=\"left\" width=\"33.33%\"/></colgroup><tbody><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Potency</content></td><td align=\"left\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">NDC</content></td><td align=\"left\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\"><content styleCode=\"bold\">Assay Color Code</content></td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule\" valign=\"top\">250 IU FVIII/5 mL single-dose vial</td><td align=\"left\" valign=\"top\">68516-4616-1</td><td align=\"left\" styleCode=\"Lrule Rrule\" valign=\"top\">250 IU FVIII Range &#x2013; gray box</td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\">500 IU FVIII/5 mL single-dose vial</td><td align=\"left\" styleCode=\"Rrule Toprule\" valign=\"top\">68516-4617-1</td><td align=\"left\" styleCode=\"Rrule Toprule\" valign=\"top\">500 IU FVIII Range - green box</td></tr><tr><td align=\"left\" styleCode=\"Lrule Toprule\" valign=\"top\">1000 IU FVIII/10 mL single-dose vial</td><td align=\"left\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\">68516-4618-2</td><td align=\"left\" styleCode=\"Rrule Toprule\" valign=\"top\">1000 IU FVIII Range &#x2013; blue box</td></tr><tr><td align=\"left\" styleCode=\"Lrule Rrule Toprule\" valign=\"top\">1500 IU FVIII/10 mL single-dose vial</td><td align=\"left\" styleCode=\"Rrule Toprule\" valign=\"top\">68516-4619-2</td><td align=\"left\" styleCode=\"Rrule Toprule\" valign=\"top\">1500 IU FVIII Range &#x2013; orange box</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"top\">2000 IU FVIII/10 mL single-dose vial</td><td align=\"left\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\">68516-4620-2</td><td align=\"left\" styleCode=\"Botrule Rrule Toprule\" valign=\"top\">2000 IU FVIII Range - magenta box</td></tr></tbody></table>"],"id":"62efdce0-9d8e-47ee-954c-9a4cbdfb525d","indications_and_usage":["1 INDICATIONS AND USAGE ALPHANATE is indicated for: Treatment and prevention of bleeding episodes and perioperative management in adult and pediatric patients with Factor VIII (FVIII) deficiency due to hemophilia A. Perioperative management in adult and pediatric patients with Type 1 and Type 2 von Willebrand Disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. Perioperative management in minor surgery in adult and pediatric patients with Type 3 VWD. ALPHANATE (antihemophilic factor/von Willebrand factor complex [human]), is indicated for: Treatment and prevention of bleeding episodes and perioperative management in adult and pediatric patients with Factor VIII (FVIII) deficiency due to hemophilia A. ( 1 ) Perioperative management in adult and pediatric patients with Type 1 and Type 2 von Willebrand Disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. ( 1 ) Perioperative management in minor surgery in adult and pediatric patients with Type 3 VWD. ( 1 )"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient and/or caregiver: To contact their healthcare provider or go to the emergency department right away if a hypersensitivity reaction occurs. Early signs of hypersensitivity reactions may include rash, hives, itching, facial swelling, tightness of the chest, and wheezing [see Warnings and Precautions (5.1) ] . To contact their healthcare provider or treatment center for further treatment and/or assessment if they experience a lack of clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor [see Warnings and Precautions (5.2) ] . To contact their healthcare provider or go to the emergency department right away if a thromboembolic event should occur [see Warnings and Precautions (5.3) ] . That despite stringent procedures designed to reduce risk, the risk of transmitting infectious agents cannot be totally eliminated. Advise patients, especially pregnant women and immunocompromised individuals, to report any signs and symptoms of fever, rash, joint pain, or sore throat, to their healthcare provider immediately [see Warnings and Precautions (5.6) ] . Manufactured by: Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. U.S. License No. 1694 3070770"],"labor_and_delivery":["8.2 Lactation Risk Summary There is no information regarding the presence of ALPHANATE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ALPHANATE and any potential adverse effects on the breast-fed infant from ALPHANATE or from the underlying maternal condition."],"mechanism_of_action":["12.1 Mechanism of Action ALPHANATE contains antihemophilic factor (FVIII) and von Willebrand factor (VWF), constituents of normal plasma. FVIII is an essential cofactor in activation of factor X leading to formation of thrombin and fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; it also serves as a stabilizing carrier protein for the procoagulant protein FVIII. After administration, ALPHANATE temporarily replaces the missing coagulation FVIII and VWF needed for effective hemostasis."],"openfda":{"application_number":["BLA102475"],"brand_name":["Alphanate"],"generic_name":["ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN)"],"is_original_packager":[true],"manufacturer_name":["GRIFOLS USA, LLC"],"package_ndc":["68516-4611-1","68516-4605-1","68516-1001-1","68516-4616-1","76297-002-02","68516-4612-1","68516-4606-1","68516-4617-1","68516-4613-2","68516-4607-2","68516-1002-2","68516-4618-2","76297-002-12","68516-4614-2","68516-4608-2","68516-4619-2","68516-4615-2","68516-4610-2","68516-4620-2"],"product_ndc":["68516-4616","68516-4611","68516-4612","68516-4617","68516-4613","68516-4618","68516-4614","68516-4619","68516-4615","68516-4620"],"product_type":["PLASMA DERIVATIVE"],"route":["INTRAVENOUS"],"rxcui":["1661332","1661345"],"spl_id":["62efdce0-9d8e-47ee-954c-9a4cbdfb525d"],"spl_set_id":["5a7aea94-654c-4113-9014-c3137de0a931"]},"package_label_principal_display_panel":["Principal Display Panel – 250 IU Vial Label NDC 68516-4605-1 250 IU FVIII Range Antihemophilic Factor/ von Willebrand Factor Complex (Human) Alphanate ® 5 mL Solvent Detergent / Heat Treated Storage: Store at temperatures not exceeding 25 °C (77 °F). Rx only. Single dose container for intravenous administration only. GRIFOLS U.S. License No. 1694 Instructions: Reconstitute with 5 mL of Sterile Water for Injection, USP. Administer promptly after reconstitution and do not refrigerate. Discard unused contents. For information on dosage and directions for administration, see accompanying pamphlet. Contains no preservatives. The patient and physician should discuss the risks and benefits of this product. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. Lot EXP IU FVIII/Vial IU VWF:RCo/Vial 3063712 Lot IU FVIII/Vial IU VWF:RCo/Vial Alphanate ® 5 mL NDC 68516-4605-1","Principal Display Panel – 250 IU Carton Label NDC 68516-4616-1 250 IU FVIII Range Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate ® Solvent Detergent / Heat Treated Rx only For Intravenous Administration 5 mL GRIFOLS Contents: One vial Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate ® , one vial 5 mL Sterile Water for Injection, USP, one Mix2Vial ® filter transfer set, and directions for use. Composition: Factor VIII, von Willebrand Factor, Arginine, Albumin and Histidine. Contains no preservatives. Administer within three hours of reconstitution. Discard unused content. GRIFOLS Warning: This product is prepared from large pools of human plasma. Human blood and its components may transmit infectious agents. See package insert, WARNINGS AND PRECAUTIONS. Instructions: The patient and physician should discuss the risks and benefits of this product. For information on dosage and directions for administration, see enclosed package insert. Storage: Store at temperatures not exceeding 25 °C (77 °F). Do not freeze. Single dose container for intravenous administration only. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, USA U.S. License No. 1694 GRIFOLS 3070771 GTIN 00368516461617 LOT XXXXXXXXXX EXP DDMMMYYYY SN XXXXXXXXXX XXXXXX IU FVIII/Vial XXXX IU VWF: RCo/Vial XXXX","Principal Display Panel – 500 IU Vial Label NDC 68516-4606-1 500 IU FVIII Range Antihemophilic Factor/ von Willebrand Factor Complex (Human) Alphanate ® 5 mL Solvent Detergent / Heat Treated Storage: Store at temperatures not exceeding 25 °C (77 °F). Rx only. Single dose container for intravenous administration only. GRIFOLS U.S. License No. 1694 Instructions: Reconstitute with 5 mL of Sterile Water for Injection, USP. Administer promptly after reconstitution and do not refrigerate. Discard unused contents. For information on dosage and directions for administration, see accompanying pamphlet. Contains no preservatives. The patient and physician should discuss the risks and benefits of this product. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. Lot EXP IU FVIII/Vial IU VWF:RCo/Vial 3063710 Lot IU FVIII/Vial IU VWF:RCo/Vial Alphanate ® 5 mL NDC 68516-4606-1","Principal Display Panel – 500 IU Carton Label NDC 68516-4617-1 500 IU FVIII Range Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate ® Solvent Detergent / Heat Treated Rx only For Intravenous Administration 5 mL GRIFOLS Contents: One vial Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate ® , one vial 5 mL Sterile Water for Injection, USP, one Mix2Vial ® filter transfer set, and directions for use. Composition: Factor VIII, von Willebrand Factor, Arginine, Albumin and Histidine. Contains no preservatives. Administer within three hours of reconstitution. Discard unused contents. GRIFOLS Warning: This product is prepared from large pools of human plasma. Human blood and its components may transmit infectious agents. See package insert, WARNINGS AND PRECAUTIONS. Instructions: The patient and physician should discuss the risks and benefits of this product. For information on dosage and directions for administration, see enclosed package insert. Storage: Store at temperatures not exceeding 25 °C (77 °F). Do not freeze. Single dose container for intravenous administration only. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, USA U.S. License No. 1694 GRIFOLS 3070772 GTIN 00368516461716 LOT XXXXXXXXXX EXP DDMMMYYYY SN XXXXXXXXXX XXXXXX IU FVIII/Vial XXXX IU VWF: RCo/Vial XXXX","Principal Display Panel – 1000 IU Vial Label NDC 68516-4607-2 1000 IU FVIII Range Antihemophilic Factor/ von Willebrand Factor Complex (Human) Alphanate ® 10 mL Solvent Detergent / Heat Treated Storage: Store at temperatures not exceeding 25 °C (77 °F). Rx only. Single dose container for intravenous administration only. GRIFOLS U.S. License No. 1694 Instructions: Reconstitute with 10 mL of Sterile Water for Injection, USP. Administer promptly after reconstitution and do not refrigerate. Discard unused contents. For information on dosage and directions for administration, see accompanying pamphlet. Contains no preservatives. The patient and physician should discuss the risks and benefits of this product. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. Lot EXP IU FVIII/Vial IU VWF:RCo/Vial 3063708 Lot IU FVIII/Vial IU VWF:RCo/Vial Alphanate ® 10 mL NDC 68516-4607-2","Principal Display Panel – 1000 IU Carton Label NDC 68516-4618-2 1000 IU FVIII Range Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate ® Solvent Detergent / Heat Treated Rx only For Intravenous Administration 10 mL GRIFOLS Contents: One vial Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate ® , one vial 10 mL Sterile Water for Injection, USP, one Mix2Vial ® filter transfer set, and directions for use. Composition: Factor VIII, von Willebrand Factor, Arginine, Albumin and Histidine. Contains no preservatives. Administer within three hours of reconstitution. Discard unused contents. GRIFOLS Warning: This product is prepared from large pools of human plasma. Human blood and its components may transmit infectious agents. See package insert, WARNINGS AND PRECAUTIONS. Instructions: The patient and physician should discuss the risks and benefits of this product. For information on dosage and directions for administration, see enclosed package insert. Storage: Store at temperatures not exceeding 25 °C (77 °F). Do not freeze. Single dose container for intravenous administration only. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, USA U.S. License No. 1694 GRIFOLS 3070773 GTIN 00368516461822 LOT XXXXXXXXXX EXP DDMMMYYYY SN XXXXXXXXXX XXXXXX IU FVIII/Vial XXXX IU VWF: RCo/Vial XXXX","Principal Display Panel – 1500 IU Vial Label NDC 68516-4608-2 1500 IU FVIII Range Antihemophilic Factor/ von Willebrand Factor Complex (Human) Alphanate ® 10 mL Solvent Detergent / Heat Treated Storage: Store at temperatures not exceeding 25 °C (77 °F). Rx only. Single dose container for intravenous administration only. GRIFOLS U.S. License No. 1694 Instructions: Reconstitute with 10 mL of Sterile Water for Injection, USP. Administer promptly after reconstitution and do not refrigerate. Discard unused contents. For information on dosage and directions for administration, see accompanying pamphlet. Contains no preservatives. The patient and physician should discuss the risks and benefits of this product. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. Lot EXP IU FVIII/Vial IU VWF:RCo/Vial 3063706 Lot IU FVIII/Vial IU VWF:RCo/Vial Alphanate ® 10 mL NDC 68516-4608-2","Principal Display Panel – 1500 IU Carton Label NDC 68516-4619-2 1500 IU FVIII Range Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate ® Solvent Detergent / Heat Treated Rx only For Intravenous Administration 10 mL GRIFOLS Contents: One vial Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate ® , one vial 10 mL Sterile Water for Injection, USP, one Mix2Vial ® filter transfer set, and directions for use. Composition: Factor VIII, von Willebrand Factor, Arginine, Albumin and Histidine. Contains no preservatives. Administer within three hours of reconstitution. Discard unused contents. GRIFOLS Warning: This product is prepared from large pools of human plasma. Human blood and its components may transmit infectious agents. See package insert, WARNINGS AND PRECAUTIONS. Instructions: The patient and physician should discuss the risks and benefits of this product. For information on dosage and directions for administration, see enclosed package insert. Storage: Store at temperatures not exceeding 25 °C (77 °F). Do not freeze. Single dose container for intravenous administration only. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, USA U.S. License No. 1694 GRIFOLS 3070774 GTIN 00368516461921 LOT XXXXXXXXXX EXP DDMMMYYYY SN XXXXXXXXXX XXXXXX IU FVIII/Vial XXXX IU VWF: RCo/Vial XXXX","Principal Display Panel – 2000 IU Vial Label NDC 68516-4610-2 2000 IU FVIII Range Antihemophilic Factor/ von Willebrand Factor Complex (Human) Alphanate ® 10 mL Solvent Detergent / Heat Treated Storage: Store at temperatures not exceeding 25 °C (77 °F). Rx only. Single dose container for intravenous administration only. GRIFOLS U.S. License No. 1694 Instructions: Reconstitute with 10 mL of Sterile Water for Injection, USP. Administer promptly after reconstitution and do not refrigerate. Discard unused contents. For information on dosage and directions for administration, see accompanying pamphlet. Contains no preservatives. The patient and physician should discuss the risks and benefits of this product. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, U.S.A. Lot EXP IU FVIII/Vial IU VWF:RCo/Vial 3063704 Lot 10 IU FVIII/Vial IU VWF:RCo/Vial Alphanate ® 10 mL NDC 68516-4608-2","Principal Display Panel – 2000 IU Carton Label NDC 68516-4620-2 2000 IU FVIII Range Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate ® Solvent Detergent / Heat Treated Rx only For Intravenous Administration 10 mL GRIFOLS Contents: One vial Antihemophilic Factor/von Willebrand Factor Complex (Human), Alphanate ® , one vial 10 mL Sterile Water for Injection, USP, one Mix2Vial ® filter transfer set, and directions for use. Composition: Factor VIII, von Willebrand Factor, Arginine, Albumin and Histidine. Contains no preservatives. Administer within three hours of reconstitution. Discard unused contents. GRIFOLS Warning: This product is prepared from large pools of human plasma. Human blood and its components may transmit infectious agents. See package insert, WARNINGS AND PRECAUTIONS. Instructions: The patient and physician should discuss the risks and benefits of this product. For information on dosage and directions for administration, see enclosed package insert. Storage: Store at temperatures not exceeding 25 °C (77 °F). Do not freeze. Single dose container for intravenous administration only. Grifols Biologicals LLC 5555 Valley Boulevard Los Angeles, CA 90032, USA U.S. License No. 1694 GRIFOLS 3070775 GTIN 00368516462027 LOT XXXXXXXXXX EXP DDMMMYYYY SN XXXXXXXXXX XXXXXX IU FVIII/Vial XXXX IU VWF: RCo/Vial XXXX","","Principal Display Panel – 5 mL Vial Label NDC 76297-002-02 Sterile Water for Injection, USP 5 mL Rx only 3057422 For reconstitution of accompanying product Single-Dose Container, Nonpyrogenic Do not use unless clear. No antimicrobial agent or other substance has been added. Do not use for intravascular injection without making approximately isotonic by addition of suitable solute. Discard unused portion. Mfd by: Laboratorios Grifols, S.A. Parets del Vallès, Barcelona 08150 Spain Lot EXP Principal Display Panel – 10 mL Vial Label NDC 76297-002-12 Sterile Water for Injection, USP 10 mL Rx only 3057423 For reconstitution of accompanying product Single-Dose Container, Nonpyrogenic Do not use unless clear. No antimicrobial agent or other substance has been added. Do not use for intravascular injection without making approximately isotonic by addition of suitable solute. Discard unused portion. Mfd by: Laboratorios Grifols, S.A. Parets del Vallès, Barcelona 08150 Spain Lot EXP"],"pediatric_use":["8.4 Pediatric Use Hemophilia A The safety and efficacy of ALPHANATE have been established in pediatric patients with Hemophilia A. There were 21 patients aged 7 to 16 years enrolled in a single clinical trial who received ALPHANATE weekly for prophylaxis or anytime for suspected bleeds. They were successfully treated for 1499 bleeding episodes or as prophylaxis to prevent them (e.g. pain in the joint). The median number of units needed to treat the bleeds was 420 IU, with a range of 210 IU to 1620 IU. Von Willebrand Disease The safety and efficacy of ALPHANATE have been established in pediatric patients with Von Willebrand Disease. The hemostatic efficacy of ALPHANATE has been studied in 20 pediatric patients (ages 7 to 18 years) with VWD. Based on the data from a subset of these patients, age had no effect on the pharmacokinetics of VWF:RCo."],"pharmacodynamics":["12.2 Pharmacodynamics There have been no specific pharmacodynamic studies on ALPHANATE."],"pharmacokinetics":["12.3 Pharmacokinetics Pharmacokinetics in Hemophilia A Following the administration of ALPHANATE during clinical trials, the mean in vivo half-life of FVIII observed in 12 adult patients with severe hemophilia A was 17.9 ± 9.6 hours. In this same study, the in vivo recovery was 96.7 ± 14.5% at 10 minutes post-infusion. Recovery at 10 minutes post-infusion was 2.4 ± 0.4 IU FVIII rise/dL plasma per IU FVIII infused/kg body weight. Pharmacokinetics in von Willebrand Disease (VWD) A pharmacokinetic crossover study was conducted in 14 non-bleeding patients with VWD (1 type 1, 2 type 2A, and 11 type 3) comparing the pharmacokinetics of ALPHANATE (A-SD/HT) and an earlier formulation, ALPHANATE (A-SD). Patients received, in random order at least seven days apart, a single intravenous dose of each product, 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg in patients younger than 18 years of age). Pharmacokinetic parameters were similar for the two products and indicated that they were biochemically equivalent. Pharmacokinetic analysis of ALPHANATE (A-SD/HT) in the 14 patients revealed the following results: the median plasma levels (% normal) of VWF:RCo rose from 10 IU/dL (range: 10 to 27 IU/dL) at baseline to 206 IU/dL (range: 87 to 440 IU/dL) 15 minutes post-infusion; median plasma levels of FVIII:C rose from 5 IU/dL (range: 2 to 114 IU/dL) to 206 IU/dL (range: 110 to 421 IU/dL). The median bleeding time (BT) prior to infusion was 30 minutes (mean, 28.8 ± 4.41 minutes; range: 13.5 to 30 minutes), which shortened to 10.38 minutes (mean, 10.4 ± 3.2 minutes; range: 6 to 16 minutes) 1 hour post-infusion. Following infusion of ALPHANATE (A-SD/HT), the median half-lives for VWF:RCo, FVIII:C and VWF:Ag were 6.91 hours (range: 3.8 to 16.22 hours), 20.92 hours (range: 7.19 to 32.2 hours), and 12.8 hours (range: 10.34 to 17.45 hours), respectively. The median incremental in vivo recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [range: 1.28 to 5.73 (IU/dL)/(IU/kg)] for VWF:RCo and 1.95 (IU/dL)/(IU/kg) [range: 1.33 to 3.32 (IU/dL)/(IU/kg)] for FVIII:C. The pharmacokinetic data in VWD are summarized in Table 6 . Table 6: Pharmacokinetic Data in von Willebrand Disease Parameter Plasma VWF:RCo (Mean ± SD) Plasma FVIII:C (Mean ± SD) Plasma VWF:Ag (Mean ± SD) Number of patients 14 14 14 Mean plasma levels (IU/dL): Baseline 11.86 ± 4.97 21.00 ± 33.83 – Mean plasma levels (IU/dL): 15 minutes post infusion 215.50 ± 101.70 215.29 ± 94.26 – T½ (Half-life in hours) 7.67 ± 3.32 21.58 ± 7.79 13.06 ± 2.20 Incremental in vivo recovery in (IU/dL)/(IU/kg) 3.29 ± 1.46 2.13 ± 0.58 – Following infusion of both ALPHANATE (A-SD) and ALPHANATE (A-SD/HT), an increase in the size of VWF multimers was seen and persisted for at least 24 hours. The shortening of the BT was transient, lasting less than 6 hours following treatment and did not correlate with the presence of large and intermediate size VWF multimers."],"pharmacokinetics_table":["<table ID=\"t6\" cellpadding=\"4\" styleCode=\"Noautorules\" width=\"100%\"><caption>Table 6: Pharmacokinetic Data in von Willebrand Disease</caption><colgroup><col align=\"left\" width=\"31.07%\"/><col align=\"left\" width=\"22.37%\"/><col align=\"left\" width=\"23.42%\"/><col align=\"left\" width=\"23.12%\"/></colgroup><tbody><tr><td align=\"center\" styleCode=\"Botrule Lrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Parameter</content> </td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma VWF:RCo</content> (Mean &#xB1; SD)</td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma FVIII:C</content> (Mean &#xB1; SD)</td><td align=\"center\" styleCode=\"Botrule Rrule Toprule\" valign=\"bottom\"><content styleCode=\"bold\">Plasma VWF:Ag</content> (Mean &#xB1; SD)</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Number of patients</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">14</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Mean plasma levels (IU/dL):  Baseline</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">11.86 &#xB1; 4.97</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">21.00 &#xB1; 33.83</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Mean plasma levels (IU/dL):  15 minutes post infusion</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">215.50 &#xB1; 101.70</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">215.29 &#xB1; 94.26</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">T&#xBD; (Half-life in hours)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">7.67 &#xB1; 3.32</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">21.58 &#xB1; 7.79</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">13.06 &#xB1; 2.20</td></tr><tr><td align=\"left\" styleCode=\"Botrule Lrule Rrule\" valign=\"bottom\">Incremental <content styleCode=\"italics\">in vivo </content>recovery  in (IU/dL)/(IU/kg)</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">3.29 &#xB1; 1.46</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">2.13 &#xB1; 0.58</td><td align=\"center\" styleCode=\"Botrule Rrule\" valign=\"bottom\">&#x2013;</td></tr></tbody></table>"],"pregnancy":["8.1 Pregnancy Risk Summary There are no data on the use of ALPHANATE in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted with ALPHANATE. It is also not known whether ALPHANATE can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Use ALPHANATE in pregnant women only if clearly needed. The estimated background risk of major birth defects and miscarriage in the U.S. general population in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown."],"recent_major_changes":["Indications and Usage ( 1 ) 7/2026 Dosage and Administration, Dose ( 2.1 ) 7/2026 Contraindications ( 4 ) 7/2026 Warnings and Precautions ( 5.1 )( 5.2 )( 5.3 )( 5.4 )( 5.5 )( 5.7 ) 7/2026"],"recent_major_changes_table":["<table cellpadding=\"0\" styleCode=\"Noautorules\" width=\"70%\"><tbody><tr><td>Indications and Usage (<linkHtml href=\"#s1\">1</linkHtml>) </td><td>7/2026 </td></tr><tr><td>Dosage and Administration, Dose (<linkHtml href=\"#s5\">2.1</linkHtml>) </td><td>7/2026 </td></tr><tr><td>Contraindications (<linkHtml href=\"#s10\">4</linkHtml>) </td><td>7/2026 </td></tr><tr><td>Warnings and Precautions (<linkHtml href=\"#s12\">5.1</linkHtml>)(<linkHtml href=\"#s13\">5.2</linkHtml>)(<linkHtml href=\"#s14\">5.3</linkHtml>)(<linkHtml href=\"#s15\">5.4</linkHtml>)(<linkHtml href=\"#s16\">5.5</linkHtml>)(<linkHtml href=\"#ID_418ce908-f0c4-cda3-e382-d0f9ab652c4c\">5.7</linkHtml>) </td><td>7/2026 </td></tr></tbody></table>"],"set_id":"5a7aea94-654c-4113-9014-c3137de0a931","spl_product_data_elements":["Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) Alphanate Antihemophilic Factor/von Willebrand Factor Complex (Human) HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX Albumin Human arginine histidine Sterile Water Water water Water Figures 1-8 5mL Sterile Water Label 10mL Sterile Water Label Vial Label 250IU 5mL Vial Label 500IU 5mL Carton Label 500IU 5mL Vial Label 1000IU 10mL Carton Label 1000IU 10mL Vial Label 1500IU 10mL Carton Label 1500IU 10mL Vial Label 2000IU 10mL Carton Label 2000 IU 10mL Carton Label 250IU 5mL"],"storage_and_handling":["Storage and Handling ALPHANATE is stable for three years, up to the expiration date printed on its label, provided that the storage temperature does not exceed 25 °C (77 °F). Do not freeze."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no data on the use of ALPHANATE in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted with ALPHANATE. It is also not known whether ALPHANATE can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Use ALPHANATE in pregnant women only if clearly needed. The estimated background risk of major birth defects and miscarriage in the U.S. general population in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. 8.2 Lactation Risk Summary There is no information regarding the presence of ALPHANATE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ALPHANATE and any potential adverse effects on the breast-fed infant from ALPHANATE or from the underlying maternal condition. 8.4 Pediatric Use Hemophilia A The safety and efficacy of ALPHANATE have been established in pediatric patients with Hemophilia A. There were 21 patients aged 7 to 16 years enrolled in a single clinical trial who received ALPHANATE weekly for prophylaxis or anytime for suspected bleeds. They were successfully treated for 1499 bleeding episodes or as prophylaxis to prevent them (e.g. pain in the joint). The median number of units needed to treat the bleeds was 420 IU, with a range of 210 IU to 1620 IU. Von Willebrand Disease The safety and efficacy of ALPHANATE have been established in pediatric patients with Von Willebrand Disease. The hemostatic efficacy of ALPHANATE has been studied in 20 pediatric patients (ages 7 to 18 years) with VWD. Based on the data from a subset of these patients, age had no effect on the pharmacokinetics of VWF:RCo. 8.5 Geriatric Use The safety and effectiveness of ALPHANATE have not been studied in geriatric patients ≥ 65 years of age."],"version":"29","warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Anaphylaxis or severe hypersensitivity reactions have occurred. Discontinue treatment with ALPHANATE and administer appropriate emergency treatment should symptoms of anaphylaxis or severe hypersensitivity occur. ( 5.1 ) Neutralizing antibodies to Factor VIII and VWF have occurred. ( 5.2 ) Thromboembolic events (TE) have occurred in patients with VWD, especially with known risk factors. Monitor patients for signs and symptoms of TE. ( 5.3 ) Intravascular hemolysis may occur with infusion of large doses of FVIII/von Willebrand Factor Complex. Should this condition occur and lead to progressive hemolytic anemia, discontinue administration of ALPHANATE and consider alternative therapy. ( 5.4 ) Rapid administration may result in vasomotor reactions. ( 5.5 ) ALPHANATE is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.6 ) Perform assays to determine if FVIII/VWF inhibitors are present. ( 5.7 ) 5.1 Hypersensitivity Reactions Severe hypersensitivity reactions including anaphylaxis have occurred during or after ALPHANATE administration. Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. Discontinue use of ALPHANATE if hypersensitivity symptoms occur and initiate appropriate treatment. 5.2 Neutralizing Antibodies Neutralizing antibodies (inhibitors) to von Willebrand Factor and Factor VIII have occurred following administration of ALPHANATE. Monitor patients for the development of neutralizing antibodies by appropriate clinical observations and laboratory tests. If expected plasma FVIII/VWF activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an appropriate assay that measures FVIII/VWF inhibitor concentration. 5.3 Thromboembolic Events Thromboembolic events have been reported with ALPHANATE administration [see Adverse Reactions (6) ]. Risk factors for thromboembolic events include patients with von Willebrand Disease, elderly age, previous thrombosis, metabolic syndrome, cancer, surgery, oral contraceptive and hormone therapy, diabetes, hypertension, hyperlipidemia, smoking, and pregnancy. Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, during continued treatment with ALPHANATE. Consider antithrombotic measures in patients with at risk for thrombosis. [see Monitoring: Laboratory Tests (5.7) ] . 5.4 Intravascular Hemolysis Intravascular hemolysis may occur following treatment with ALPHANATE as it contains blood group specific isoagglutinins. Risk factors for hemolysis include large and/or frequent doses of ALPHANATE in patients with blood groups A, B, or AB. Monitor patients for clinical signs and symptoms of hemolysis. If hemolysis occurs, pause infusion if ongoing and manage according to clinical practice. 5.5 Vasomotor Reactions Do not administer ALPHANATE at a rate exceeding 10 mL/minute. Rapid administration of ALPHANATE may result in vasomotor reactions. 5.6 Transmissible Infectious Agents Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob Disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain virus infections, and by inactivating and/or removing certain viruses during manufacturing. [see Description (11) ]. 5.7 Monitoring: Laboratory Tests Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE. Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, particularly in patients with known risk factors."]}